Skip to main content
. 2022 Apr 6;17(4):e0266478. doi: 10.1371/journal.pone.0266478

Fig 5. CB-5083 and cytarabine or venetoclax synergistically decrease AML cell survival.

Fig 5

(A-D) THP-1 and MV4-11 cell survival was assessed in a 96-well format with increasing concentrations of CB-5083 and cytarabine or venetoclax. Following a 72-hour incubation, CellTiter-Blue Reagent was added and fluorescence/cell viability was assessed. Cell viability data was used as input for the SynergyFinder software to estimate synergy δ scores. Synergy landscape maps display δ scores for the indicated cells lines and drug combinations.